Opinions expressed by Digital Journal contributors are their own. Bringing a new biologic drug from concept to clinic is a complex journey fraught with technical and regulatory hurdles. For ...
After its founding in 1976, scientists at Genentech worked methodically toward the development of its first biotechnology product. It was nearly a decade later that the FDA approved Protropin, a ...
Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...
The weight-loss drug market is surging, with biotech firms racing to win share in a sector dominated by Novo Nordisk and Eli ...
Altasciences, a fully integrated drug development solution company, and VoxCell BioInnovation (“VoxCell”), a leader in 3D bioprinting and human-like tissue modeling, are pleased to announce a ...
Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...
Genmab will stop development of its experimental antibody therapy to treat cancer that was in late-stage trials, the Danish drugmaker said on Monday. The company had assumed sole responsibility for ...
Australian researchers have worked with global phamarceutical company MSD to co-develop a new antimalarial drug candidate designed to address the growing challenge of drug resistance and potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback